nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—CYP3A4—Estropipate—osteoporosis	0.069	0.181	CbGbCtD
Everolimus—CYP3A4—Calcitriol—osteoporosis	0.069	0.181	CbGbCtD
Everolimus—CYP3A4—Ergocalciferol—osteoporosis	0.0552	0.145	CbGbCtD
Everolimus—CYP3A4—Raloxifene—osteoporosis	0.046	0.121	CbGbCtD
Everolimus—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0445	0.117	CbGbCtD
Everolimus—CYP3A4—Cholecalciferol—osteoporosis	0.0355	0.0934	CbGbCtD
Everolimus—CYP3A4—Conjugated Estrogens—osteoporosis	0.0326	0.0858	CbGbCtD
Everolimus—CYP3A4—Estradiol—osteoporosis	0.0287	0.0753	CbGbCtD
Everolimus—MTOR—Disease—SOST—osteoporosis	0.000255	0.00151	CbGpPWpGaD
Everolimus—MTOR—Disease—PKM—osteoporosis	0.000255	0.00151	CbGpPWpGaD
Everolimus—FKBP1A—Disease—ACP5—osteoporosis	0.000253	0.0015	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IL1B—osteoporosis	0.000249	0.00147	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—IRS1—osteoporosis	0.000249	0.00147	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—IRS1—osteoporosis	0.000248	0.00146	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—IL6R—osteoporosis	0.000248	0.00146	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—IRS1—osteoporosis	0.000247	0.00146	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—IRS1—osteoporosis	0.000246	0.00145	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—IRS1—osteoporosis	0.000244	0.00144	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—IL6R—osteoporosis	0.000244	0.00144	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—IRS2—osteoporosis	0.000244	0.00144	CbGpPWpGaD
Everolimus—MTOR—Disease—PGLS—osteoporosis	0.000242	0.00143	CbGpPWpGaD
Everolimus—MTOR—Disease—ANTXR2—osteoporosis	0.000242	0.00143	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—IRS1—osteoporosis	0.000241	0.00142	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—IL6—osteoporosis	0.000237	0.0014	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TPI1—osteoporosis	0.000236	0.00139	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IRS2—osteoporosis	0.000233	0.00138	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—IL6R—osteoporosis	0.000233	0.00138	CbGpPWpGaD
Everolimus—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000232	0.00137	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—IL6R—osteoporosis	0.000232	0.00137	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—osteoporosis	0.000232	0.00137	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—IL6R—osteoporosis	0.000231	0.00136	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—IRS1—osteoporosis	0.00023	0.00136	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—IRS1—osteoporosis	0.00023	0.00136	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IRS1—osteoporosis	0.00023	0.00136	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—IL6R—osteoporosis	0.00023	0.00136	CbGpPWpGaD
Everolimus—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000229	0.00135	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—SOD2—osteoporosis	0.000228	0.00135	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MGLL—osteoporosis	0.000228	0.00135	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—IRS1—osteoporosis	0.000228	0.00135	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—IRS1—osteoporosis	0.000226	0.00133	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—IRS1—osteoporosis	0.000225	0.00133	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—LRP5—osteoporosis	0.000223	0.00131	CbGpPWpGaD
Everolimus—FKBP1A—Disease—P4HB—osteoporosis	0.000221	0.00131	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CTSK—osteoporosis	0.00022	0.0013	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—GPX1—osteoporosis	0.000218	0.00129	CbGpPWpGaD
Everolimus—FKBP1A—Disease—GAPDH—osteoporosis	0.000217	0.00128	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—osteoporosis	0.000216	0.00128	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—NFATC1—osteoporosis	0.000216	0.00128	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6R—osteoporosis	0.000216	0.00127	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—IL6R—osteoporosis	0.000216	0.00127	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—IL6R—osteoporosis	0.000216	0.00127	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	0.000214	0.00126	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—IL6R—osteoporosis	0.000214	0.00126	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	0.000214	0.00126	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—LRP6—osteoporosis	0.000213	0.00126	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—IRS1—osteoporosis	0.000213	0.00126	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—RAP1A—osteoporosis	0.000213	0.00126	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—IL6R—osteoporosis	0.000212	0.00125	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—IL6R—osteoporosis	0.000211	0.00125	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CTSK—osteoporosis	0.000211	0.00124	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NFATC1—osteoporosis	0.000207	0.00122	CbGpPWpGaD
Everolimus—MTOR—Disease—GSN—osteoporosis	0.000206	0.00121	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—ADCY5—osteoporosis	0.000205	0.00121	CbGpPWpGaD
Everolimus—FKBP1A—Disease—DKK1—osteoporosis	0.000205	0.00121	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IRS1—osteoporosis	0.000204	0.0012	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	0.000199	0.00118	CbGpPWpGaD
Everolimus—FKBP1A—Disease—WNT1—osteoporosis	0.000197	0.00117	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TGFB1—osteoporosis	0.000194	0.00114	CbGpPWpGaD
Everolimus—FKBP1A—Disease—FGA—osteoporosis	0.000192	0.00113	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6R—osteoporosis	0.000191	0.00113	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	0.00019	0.00112	CbGpPWpGaD
Everolimus—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000188	0.00111	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	0.000188	0.00111	CbGpPWpGaD
Everolimus—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.00018	0.000401	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.00018	0.000401	CcSEcCtD
Everolimus—Paraesthesia—Risedronate—osteoporosis	0.00018	0.0004	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—TLN1—osteoporosis	0.00018	0.00106	CbGpPWpGaD
Everolimus—Pruritus—Estropipate—osteoporosis	0.000179	0.000399	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—IRS2—osteoporosis	0.000179	0.00106	CbGpPWpGaD
Everolimus—Discomfort—Zoledronate—osteoporosis	0.000179	0.000398	CcSEcCtD
Everolimus—Asthenia—Alendronate—osteoporosis	0.000179	0.000398	CcSEcCtD
Everolimus—Hypersensitivity—Ibandronate—osteoporosis	0.000179	0.000398	CcSEcCtD
Everolimus—Cough—Conjugated Estrogens—osteoporosis	0.000179	0.000398	CcSEcCtD
Everolimus—MTOR—Disease—LRP5—osteoporosis	0.000179	0.00106	CbGpPWpGaD
Everolimus—Dyspnoea—Risedronate—osteoporosis	0.000179	0.000397	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—SOST—osteoporosis	0.000179	0.00105	CbGpPWpGaD
Everolimus—Hypotension—Pamidronate—osteoporosis	0.000178	0.000395	CcSEcCtD
Everolimus—Convulsion—Conjugated Estrogens—osteoporosis	0.000178	0.000395	CcSEcCtD
Everolimus—Dry mouth—Zoledronate—osteoporosis	0.000178	0.000394	CcSEcCtD
Everolimus—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000177	0.000394	CcSEcCtD
Everolimus—Fatigue—Ethinyl Estradiol—osteoporosis	0.000177	0.000394	CcSEcCtD
Everolimus—Pruritus—Alendronate—osteoporosis	0.000177	0.000393	CcSEcCtD
Everolimus—Dyspepsia—Risedronate—osteoporosis	0.000176	0.000392	CcSEcCtD
Everolimus—Eye disorder—Estradiol—osteoporosis	0.000176	0.000392	CcSEcCtD
Everolimus—Constipation—Ethinyl Estradiol—osteoporosis	0.000176	0.00039	CcSEcCtD
Everolimus—Hypersensitivity—Calcitriol—osteoporosis	0.000175	0.00039	CcSEcCtD
Everolimus—Flushing—Estradiol—osteoporosis	0.000175	0.000389	CcSEcCtD
Everolimus—Cardiac disorder—Estradiol—osteoporosis	0.000175	0.000389	CcSEcCtD
Everolimus—Chest pain—Conjugated Estrogens—osteoporosis	0.000175	0.000388	CcSEcCtD
Everolimus—Arthralgia—Conjugated Estrogens—osteoporosis	0.000175	0.000388	CcSEcCtD
Everolimus—Myalgia—Conjugated Estrogens—osteoporosis	0.000175	0.000388	CcSEcCtD
Everolimus—Asthenia—Ibandronate—osteoporosis	0.000174	0.000388	CcSEcCtD
Everolimus—Anxiety—Conjugated Estrogens—osteoporosis	0.000174	0.000387	CcSEcCtD
Everolimus—Nausea—Etidronic acid—osteoporosis	0.000174	0.000387	CcSEcCtD
Everolimus—Oedema—Zoledronate—osteoporosis	0.000174	0.000387	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000174	0.000386	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000174	0.000386	CcSEcCtD
Everolimus—Diarrhoea—Estropipate—osteoporosis	0.000173	0.000385	CcSEcCtD
Everolimus—Gastrointestinal disorder—Risedronate—osteoporosis	0.000173	0.000384	CcSEcCtD
Everolimus—MTOR—IRS-mediated signalling—IL6—osteoporosis	0.000173	0.00102	CbGpPWpGaD
Everolimus—Infection—Zoledronate—osteoporosis	0.000173	0.000384	CcSEcCtD
Everolimus—Fatigue—Risedronate—osteoporosis	0.000173	0.000384	CcSEcCtD
Everolimus—Insomnia—Pamidronate—osteoporosis	0.000172	0.000383	CcSEcCtD
Everolimus—Pruritus—Ibandronate—osteoporosis	0.000172	0.000382	CcSEcCtD
Everolimus—Constipation—Risedronate—osteoporosis	0.000171	0.000381	CcSEcCtD
Everolimus—Pain—Risedronate—osteoporosis	0.000171	0.000381	CcSEcCtD
Everolimus—Angiopathy—Estradiol—osteoporosis	0.000171	0.00038	CcSEcCtD
Everolimus—Shock—Zoledronate—osteoporosis	0.000171	0.00038	CcSEcCtD
Everolimus—FKBP1A—Disease—ENO1—osteoporosis	0.000171	0.00101	CbGpPWpGaD
Everolimus—MTOR—Disease—LRP6—osteoporosis	0.000171	0.00101	CbGpPWpGaD
Everolimus—Paraesthesia—Pamidronate—osteoporosis	0.000171	0.00038	CcSEcCtD
Everolimus—Diarrhoea—Alendronate—osteoporosis	0.000171	0.00038	CcSEcCtD
Everolimus—Asthenia—Calcitriol—osteoporosis	0.000171	0.000379	CcSEcCtD
Everolimus—Nervous system disorder—Zoledronate—osteoporosis	0.000171	0.000379	CcSEcCtD
Everolimus—Immune system disorder—Estradiol—osteoporosis	0.00017	0.000379	CcSEcCtD
Everolimus—Thrombocytopenia—Zoledronate—osteoporosis	0.00017	0.000379	CcSEcCtD
Everolimus—Mediastinal disorder—Estradiol—osteoporosis	0.00017	0.000378	CcSEcCtD
Everolimus—Dyspnoea—Pamidronate—osteoporosis	0.00017	0.000377	CcSEcCtD
Everolimus—Tachycardia—Zoledronate—osteoporosis	0.00017	0.000377	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—PSMA2—osteoporosis	0.000169	0.001	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PSMA5—osteoporosis	0.000169	0.001	CbGpPWpGaD
Everolimus—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000169	0.000376	CcSEcCtD
Everolimus—Chills—Estradiol—osteoporosis	0.000169	0.000376	CcSEcCtD
Everolimus—Somnolence—Pamidronate—osteoporosis	0.000169	0.000376	CcSEcCtD
Everolimus—Skin disorder—Zoledronate—osteoporosis	0.000169	0.000376	CcSEcCtD
Everolimus—MTOR—Immune System—IRAK3—osteoporosis	0.000169	0.000996	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PSMA2—osteoporosis	0.000169	0.000996	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PSMA5—osteoporosis	0.000169	0.000996	CbGpPWpGaD
Everolimus—Pruritus—Calcitriol—osteoporosis	0.000168	0.000374	CcSEcCtD
Everolimus—MTOR—IRS-related events—IL6—osteoporosis	0.000168	0.000993	CbGpPWpGaD
Everolimus—Hyperhidrosis—Zoledronate—osteoporosis	0.000168	0.000374	CcSEcCtD
Everolimus—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000168	0.000373	CcSEcCtD
Everolimus—Diarrhoea—Raloxifene—osteoporosis	0.000168	0.000373	CcSEcCtD
Everolimus—Dyspepsia—Pamidronate—osteoporosis	0.000168	0.000373	CcSEcCtD
Everolimus—Dizziness—Estropipate—osteoporosis	0.000168	0.000373	CcSEcCtD
Everolimus—Oedema—Conjugated Estrogens—osteoporosis	0.000168	0.000372	CcSEcCtD
Everolimus—Alopecia—Estradiol—osteoporosis	0.000167	0.000371	CcSEcCtD
Everolimus—MTOR—IRS-related events triggered by IGF1R—IL6—osteoporosis	0.000167	0.000984	CbGpPWpGaD
Everolimus—Infection—Conjugated Estrogens—osteoporosis	0.000166	0.00037	CcSEcCtD
Everolimus—Diarrhoea—Ibandronate—osteoporosis	0.000166	0.00037	CcSEcCtD
Everolimus—Anorexia—Zoledronate—osteoporosis	0.000166	0.000369	CcSEcCtD
Everolimus—Decreased appetite—Pamidronate—osteoporosis	0.000166	0.000368	CcSEcCtD
Everolimus—Mental disorder—Estradiol—osteoporosis	0.000165	0.000367	CcSEcCtD
Everolimus—Dizziness—Alendronate—osteoporosis	0.000165	0.000367	CcSEcCtD
Everolimus—Shock—Conjugated Estrogens—osteoporosis	0.000165	0.000366	CcSEcCtD
Everolimus—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000164	0.000365	CcSEcCtD
Everolimus—MTOR—Disease—LTF—osteoporosis	0.000164	0.00097	CbGpPWpGaD
Everolimus—MTOR—Disease—RPL24—osteoporosis	0.000164	0.00097	CbGpPWpGaD
Everolimus—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000164	0.000365	CcSEcCtD
Everolimus—Malnutrition—Estradiol—osteoporosis	0.000164	0.000365	CcSEcCtD
Everolimus—Erythema—Estradiol—osteoporosis	0.000164	0.000365	CcSEcCtD
Everolimus—Fatigue—Pamidronate—osteoporosis	0.000164	0.000365	CcSEcCtD
Everolimus—Gastrointestinal pain—Risedronate—osteoporosis	0.000164	0.000364	CcSEcCtD
Everolimus—Tachycardia—Conjugated Estrogens—osteoporosis	0.000164	0.000363	CcSEcCtD
Everolimus—Pain—Pamidronate—osteoporosis	0.000163	0.000362	CcSEcCtD
Everolimus—Constipation—Pamidronate—osteoporosis	0.000163	0.000362	CcSEcCtD
Everolimus—Diarrhoea—Calcitriol—osteoporosis	0.000163	0.000362	CcSEcCtD
Everolimus—Skin disorder—Conjugated Estrogens—osteoporosis	0.000163	0.000362	CcSEcCtD
Everolimus—Hypotension—Zoledronate—osteoporosis	0.000163	0.000361	CcSEcCtD
Everolimus—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000162	0.000361	CcSEcCtD
Everolimus—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000162	0.000361	CcSEcCtD
Everolimus—Dizziness—Raloxifene—osteoporosis	0.000162	0.000361	CcSEcCtD
Everolimus—MTOR—IGF1R signaling cascade—IL6—osteoporosis	0.000162	0.000959	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—IL6—osteoporosis	0.000162	0.000959	CbGpPWpGaD
Everolimus—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000162	0.00036	CcSEcCtD
Everolimus—Flatulence—Estradiol—osteoporosis	0.000162	0.00036	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—CALCR—osteoporosis	0.000162	0.000954	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTH1R—osteoporosis	0.000162	0.000954	CbGpPWpGaD
Everolimus—Vomiting—Estropipate—osteoporosis	0.000161	0.000358	CcSEcCtD
Everolimus—Dysgeusia—Estradiol—osteoporosis	0.000161	0.000357	CcSEcCtD
Everolimus—Dizziness—Ibandronate—osteoporosis	0.000161	0.000357	CcSEcCtD
Everolimus—Rash—Estropipate—osteoporosis	0.00016	0.000355	CcSEcCtD
Everolimus—Dermatitis—Estropipate—osteoporosis	0.00016	0.000355	CcSEcCtD
Everolimus—Anorexia—Conjugated Estrogens—osteoporosis	0.00016	0.000355	CcSEcCtD
Everolimus—Back pain—Estradiol—osteoporosis	0.000159	0.000353	CcSEcCtD
Everolimus—Headache—Estropipate—osteoporosis	0.000159	0.000353	CcSEcCtD
Everolimus—Vomiting—Alendronate—osteoporosis	0.000159	0.000353	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000159	0.000352	CcSEcCtD
Everolimus—Body temperature increased—Risedronate—osteoporosis	0.000158	0.000352	CcSEcCtD
Everolimus—Abdominal pain—Risedronate—osteoporosis	0.000158	0.000352	CcSEcCtD
Everolimus—Muscle spasms—Estradiol—osteoporosis	0.000158	0.000351	CcSEcCtD
Everolimus—Rash—Alendronate—osteoporosis	0.000157	0.00035	CcSEcCtD
Everolimus—Insomnia—Zoledronate—osteoporosis	0.000157	0.00035	CcSEcCtD
Everolimus—Dermatitis—Alendronate—osteoporosis	0.000157	0.00035	CcSEcCtD
Everolimus—FKBP1A—Disease—CALCA—osteoporosis	0.000157	0.000928	CbGpPWpGaD
Everolimus—Feeling abnormal—Pamidronate—osteoporosis	0.000157	0.000349	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—IRS1—osteoporosis	0.000157	0.000925	CbGpPWpGaD
Everolimus—Hypotension—Conjugated Estrogens—osteoporosis	0.000157	0.000348	CcSEcCtD
Everolimus—Headache—Alendronate—osteoporosis	0.000156	0.000348	CcSEcCtD
Everolimus—Paraesthesia—Zoledronate—osteoporosis	0.000156	0.000347	CcSEcCtD
Everolimus—Vomiting—Raloxifene—osteoporosis	0.000156	0.000347	CcSEcCtD
Everolimus—Gastrointestinal pain—Pamidronate—osteoporosis	0.000156	0.000346	CcSEcCtD
Everolimus—Dyspnoea—Zoledronate—osteoporosis	0.000155	0.000345	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—P4HB—osteoporosis	0.000155	0.000916	CbGpPWpGaD
Everolimus—Rash—Raloxifene—osteoporosis	0.000155	0.000344	CcSEcCtD
Everolimus—Dermatitis—Raloxifene—osteoporosis	0.000155	0.000344	CcSEcCtD
Everolimus—Somnolence—Zoledronate—osteoporosis	0.000155	0.000344	CcSEcCtD
Everolimus—Vomiting—Ibandronate—osteoporosis	0.000155	0.000343	CcSEcCtD
Everolimus—MTOR—Immune System—ACTG1—osteoporosis	0.000154	0.000911	CbGpPWpGaD
Everolimus—Tremor—Estradiol—osteoporosis	0.000154	0.000342	CcSEcCtD
Everolimus—Headache—Raloxifene—osteoporosis	0.000154	0.000342	CcSEcCtD
Everolimus—Rash—Ibandronate—osteoporosis	0.000153	0.000341	CcSEcCtD
Everolimus—Dermatitis—Ibandronate—osteoporosis	0.000153	0.00034	CcSEcCtD
Everolimus—Dyspepsia—Zoledronate—osteoporosis	0.000153	0.00034	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000153	0.000339	CcSEcCtD
Everolimus—Ill-defined disorder—Estradiol—osteoporosis	0.000152	0.000339	CcSEcCtD
Everolimus—Headache—Ibandronate—osteoporosis	0.000152	0.000338	CcSEcCtD
Everolimus—Insomnia—Conjugated Estrogens—osteoporosis	0.000152	0.000337	CcSEcCtD
Everolimus—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000151	0.000336	CcSEcCtD
Everolimus—Vomiting—Calcitriol—osteoporosis	0.000151	0.000336	CcSEcCtD
Everolimus—Decreased appetite—Zoledronate—osteoporosis	0.000151	0.000336	CcSEcCtD
Everolimus—Agitation—Estradiol—osteoporosis	0.000151	0.000335	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—PTH—osteoporosis	0.000151	0.000891	CbGpPWpGaD
Everolimus—Nausea—Estropipate—osteoporosis	0.000151	0.000335	CcSEcCtD
Everolimus—Body temperature increased—Pamidronate—osteoporosis	0.000151	0.000335	CcSEcCtD
Everolimus—Abdominal pain—Pamidronate—osteoporosis	0.000151	0.000335	CcSEcCtD
Everolimus—Paraesthesia—Conjugated Estrogens—osteoporosis	0.00015	0.000334	CcSEcCtD
Everolimus—Gastrointestinal disorder—Zoledronate—osteoporosis	0.00015	0.000334	CcSEcCtD
Everolimus—Angioedema—Estradiol—osteoporosis	0.00015	0.000334	CcSEcCtD
Everolimus—Rash—Calcitriol—osteoporosis	0.00015	0.000333	CcSEcCtD
Everolimus—Fatigue—Zoledronate—osteoporosis	0.00015	0.000333	CcSEcCtD
Everolimus—Dermatitis—Calcitriol—osteoporosis	0.00015	0.000333	CcSEcCtD
Everolimus—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000149	0.000332	CcSEcCtD
Everolimus—MTOR—Innate Immune System—KL—osteoporosis	0.000149	0.000881	CbGpPWpGaD
Everolimus—Headache—Calcitriol—osteoporosis	0.000149	0.000331	CcSEcCtD
Everolimus—Somnolence—Conjugated Estrogens—osteoporosis	0.000149	0.000331	CcSEcCtD
Everolimus—Constipation—Zoledronate—osteoporosis	0.000149	0.000331	CcSEcCtD
Everolimus—Pain—Zoledronate—osteoporosis	0.000149	0.000331	CcSEcCtD
Everolimus—Nausea—Alendronate—osteoporosis	0.000148	0.00033	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—RAP1A—osteoporosis	0.000148	0.000875	CbGpPWpGaD
Everolimus—Malaise—Estradiol—osteoporosis	0.000148	0.000329	CcSEcCtD
Everolimus—Hypersensitivity—Risedronate—osteoporosis	0.000148	0.000328	CcSEcCtD
Everolimus—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000147	0.000328	CcSEcCtD
Everolimus—Asthenia—Ethinyl Estradiol—osteoporosis	0.000147	0.000328	CcSEcCtD
Everolimus—Syncope—Estradiol—osteoporosis	0.000147	0.000327	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—IL6R—osteoporosis	0.000147	0.000868	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CNR2—osteoporosis	0.000147	0.000868	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IL6—osteoporosis	0.000146	0.000862	CbGpPWpGaD
Everolimus—Nausea—Raloxifene—osteoporosis	0.000146	0.000324	CcSEcCtD
Everolimus—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000146	0.000324	CcSEcCtD
Everolimus—Pruritus—Ethinyl Estradiol—osteoporosis	0.000145	0.000323	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—MYC—osteoporosis	0.000145	0.000858	CbGpPWpGaD
Everolimus—Palpitations—Estradiol—osteoporosis	0.000145	0.000323	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—NFATC1—osteoporosis	0.000145	0.000854	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000145	0.000321	CcSEcCtD
Everolimus—Fatigue—Conjugated Estrogens—osteoporosis	0.000144	0.000321	CcSEcCtD
Everolimus—Nausea—Ibandronate—osteoporosis	0.000144	0.000321	CcSEcCtD
Everolimus—Loss of consciousness—Estradiol—osteoporosis	0.000144	0.000321	CcSEcCtD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—osteoporosis	0.000144	0.000849	CbGpPWpGaD
Everolimus—Asthenia—Risedronate—osteoporosis	0.000144	0.000319	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—DKK1—osteoporosis	0.000144	0.000847	CbGpPWpGaD
Everolimus—Feeling abnormal—Zoledronate—osteoporosis	0.000143	0.000319	CcSEcCtD
Everolimus—Cough—Estradiol—osteoporosis	0.000143	0.000319	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—KL—osteoporosis	0.000143	0.000846	CbGpPWpGaD
Everolimus—Constipation—Conjugated Estrogens—osteoporosis	0.000143	0.000318	CcSEcCtD
Everolimus—Pain—Conjugated Estrogens—osteoporosis	0.000143	0.000318	CcSEcCtD
Everolimus—FKBP1A—Disease—KL—osteoporosis	0.000143	0.000843	CbGpPWpGaD
Everolimus—MTOR—Disease—ACP5—osteoporosis	0.000143	0.000841	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Zoledronate—osteoporosis	0.000142	0.000316	CcSEcCtD
Everolimus—Hypertension—Estradiol—osteoporosis	0.000142	0.000315	CcSEcCtD
Everolimus—Pruritus—Risedronate—osteoporosis	0.000142	0.000315	CcSEcCtD
Everolimus—Nausea—Calcitriol—osteoporosis	0.000141	0.000314	CcSEcCtD
Everolimus—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000141	0.000312	CcSEcCtD
Everolimus—Hypersensitivity—Pamidronate—osteoporosis	0.00014	0.000312	CcSEcCtD
Everolimus—Myalgia—Estradiol—osteoporosis	0.00014	0.000311	CcSEcCtD
Everolimus—Arthralgia—Estradiol—osteoporosis	0.00014	0.000311	CcSEcCtD
Everolimus—Chest pain—Estradiol—osteoporosis	0.00014	0.000311	CcSEcCtD
Everolimus—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.00014	0.000824	CbGpPWpGaD
Everolimus—Anxiety—Estradiol—osteoporosis	0.000139	0.00031	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000139	0.000309	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—WNT1—osteoporosis	0.000138	0.000816	CbGpPWpGaD
Everolimus—Discomfort—Estradiol—osteoporosis	0.000138	0.000307	CcSEcCtD
Everolimus—Abdominal pain—Zoledronate—osteoporosis	0.000138	0.000306	CcSEcCtD
Everolimus—Body temperature increased—Zoledronate—osteoporosis	0.000138	0.000306	CcSEcCtD
Everolimus—Diarrhoea—Risedronate—osteoporosis	0.000137	0.000305	CcSEcCtD
Everolimus—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000137	0.000304	CcSEcCtD
Everolimus—Dry mouth—Estradiol—osteoporosis	0.000137	0.000304	CcSEcCtD
Everolimus—Asthenia—Pamidronate—osteoporosis	0.000137	0.000304	CcSEcCtD
Everolimus—Dizziness—Ethinyl Estradiol—osteoporosis	0.000136	0.000302	CcSEcCtD
Everolimus—MTOR—Signaling by VEGF—IL6—osteoporosis	0.000136	0.000802	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—IL6—osteoporosis	0.000135	0.000796	CbGpPWpGaD
Everolimus—Pruritus—Pamidronate—osteoporosis	0.000135	0.000299	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—FGA—osteoporosis	0.000134	0.000794	CbGpPWpGaD
Everolimus—Oedema—Estradiol—osteoporosis	0.000134	0.000298	CcSEcCtD
Everolimus—Infection—Estradiol—osteoporosis	0.000133	0.000296	CcSEcCtD
Everolimus—Dizziness—Risedronate—osteoporosis	0.000133	0.000294	CcSEcCtD
Everolimus—MTOR—Disease—TPI1—osteoporosis	0.000132	0.000782	CbGpPWpGaD
Everolimus—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000132	0.000294	CcSEcCtD
Everolimus—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000132	0.000294	CcSEcCtD
Everolimus—Shock—Estradiol—osteoporosis	0.000132	0.000293	CcSEcCtD
Everolimus—Nervous system disorder—Estradiol—osteoporosis	0.000131	0.000292	CcSEcCtD
Everolimus—Tachycardia—Estradiol—osteoporosis	0.000131	0.000291	CcSEcCtD
Everolimus—Vomiting—Ethinyl Estradiol—osteoporosis	0.000131	0.00029	CcSEcCtD
Everolimus—Diarrhoea—Pamidronate—osteoporosis	0.00013	0.00029	CcSEcCtD
Everolimus—Skin disorder—Estradiol—osteoporosis	0.00013	0.000289	CcSEcCtD
Everolimus—Hyperhidrosis—Estradiol—osteoporosis	0.00013	0.000288	CcSEcCtD
Everolimus—Rash—Ethinyl Estradiol—osteoporosis	0.00013	0.000288	CcSEcCtD
Everolimus—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000129	0.000288	CcSEcCtD
Everolimus—MTOR—Immune System—RAP1A—osteoporosis	0.000129	0.000762	CbGpPWpGaD
Everolimus—Headache—Ethinyl Estradiol—osteoporosis	0.000129	0.000286	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—MGLL—osteoporosis	0.000128	0.000758	CbGpPWpGaD
Everolimus—Hypersensitivity—Zoledronate—osteoporosis	0.000128	0.000285	CcSEcCtD
Everolimus—MTOR—Immune System—CTSK—osteoporosis	0.000128	0.000755	CbGpPWpGaD
Everolimus—Vomiting—Risedronate—osteoporosis	0.000127	0.000283	CcSEcCtD
Everolimus—Rash—Risedronate—osteoporosis	0.000126	0.000281	CcSEcCtD
Everolimus—Dermatitis—Risedronate—osteoporosis	0.000126	0.00028	CcSEcCtD
Everolimus—Dizziness—Pamidronate—osteoporosis	0.000126	0.00028	CcSEcCtD
Everolimus—MTOR—Immune System—NFATC1—osteoporosis	0.000126	0.000743	CbGpPWpGaD
Everolimus—Headache—Risedronate—osteoporosis	0.000126	0.000279	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—LRP5—osteoporosis	0.000125	0.00074	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTHLH—osteoporosis	0.000125	0.000738	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—BMP2—osteoporosis	0.000125	0.000738	CbGpPWpGaD
Everolimus—Asthenia—Zoledronate—osteoporosis	0.000125	0.000277	CcSEcCtD
Everolimus—MTOR—Disease—P4HB—osteoporosis	0.000125	0.000735	CbGpPWpGaD
Everolimus—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000123	0.000274	CcSEcCtD
Everolimus—Pruritus—Zoledronate—osteoporosis	0.000123	0.000274	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—FGB—osteoporosis	0.000122	0.000722	CbGpPWpGaD
Everolimus—MTOR—Disease—GAPDH—osteoporosis	0.000122	0.000722	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000122	0.000271	CcSEcCtD
Everolimus—Nausea—Ethinyl Estradiol—osteoporosis	0.000122	0.000271	CcSEcCtD
Everolimus—Insomnia—Estradiol—osteoporosis	0.000121	0.000269	CcSEcCtD
Everolimus—Vomiting—Pamidronate—osteoporosis	0.000121	0.000269	CcSEcCtD
Everolimus—Paraesthesia—Estradiol—osteoporosis	0.00012	0.000268	CcSEcCtD
Everolimus—Asthenia—Conjugated Estrogens—osteoporosis	0.00012	0.000267	CcSEcCtD
Everolimus—Rash—Pamidronate—osteoporosis	0.00012	0.000267	CcSEcCtD
Everolimus—Dermatitis—Pamidronate—osteoporosis	0.00012	0.000267	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—LRP6—osteoporosis	0.00012	0.000707	CbGpPWpGaD
Everolimus—Dyspnoea—Estradiol—osteoporosis	0.00012	0.000266	CcSEcCtD
Everolimus—Headache—Pamidronate—osteoporosis	0.000119	0.000265	CcSEcCtD
Everolimus—Somnolence—Estradiol—osteoporosis	0.000119	0.000265	CcSEcCtD
Everolimus—Diarrhoea—Zoledronate—osteoporosis	0.000119	0.000265	CcSEcCtD
Everolimus—Nausea—Risedronate—osteoporosis	0.000119	0.000264	CcSEcCtD
Everolimus—Pruritus—Conjugated Estrogens—osteoporosis	0.000119	0.000263	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—PSMA2—osteoporosis	0.000118	0.000697	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PSMA5—osteoporosis	0.000118	0.000697	CbGpPWpGaD
Everolimus—Dyspepsia—Estradiol—osteoporosis	0.000118	0.000262	CcSEcCtD
Everolimus—MTOR—Innate Immune System—AGER—osteoporosis	0.000117	0.000693	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—ADCY5—osteoporosis	0.000117	0.00069	CbGpPWpGaD
Everolimus—Decreased appetite—Estradiol—osteoporosis	0.000117	0.000259	CcSEcCtD
Everolimus—MTOR—Disease—NFATC1—osteoporosis	0.000116	0.000686	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Estradiol—osteoporosis	0.000116	0.000257	CcSEcCtD
Everolimus—Fatigue—Estradiol—osteoporosis	0.000116	0.000257	CcSEcCtD
Everolimus—MTOR—Signaling by SCF-KIT—IL6—osteoporosis	0.000115	0.000681	CbGpPWpGaD
Everolimus—MTOR—Disease—DKK1—osteoporosis	0.000115	0.00068	CbGpPWpGaD
Everolimus—Dizziness—Zoledronate—osteoporosis	0.000115	0.000256	CcSEcCtD
Everolimus—Constipation—Estradiol—osteoporosis	0.000115	0.000255	CcSEcCtD
Everolimus—Pain—Estradiol—osteoporosis	0.000115	0.000255	CcSEcCtD
Everolimus—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000115	0.000255	CcSEcCtD
Everolimus—Nausea—Pamidronate—osteoporosis	0.000113	0.000251	CcSEcCtD
Everolimus—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.000113	0.000668	CbGpPWpGaD
Everolimus—FKBP1A—Disease—ADCY5—osteoporosis	0.000112	0.00066	CbGpPWpGaD
Everolimus—MTOR—Disease—WNT1—osteoporosis	0.000111	0.000656	CbGpPWpGaD
Everolimus—Dizziness—Conjugated Estrogens—osteoporosis	0.000111	0.000246	CcSEcCtD
Everolimus—Vomiting—Zoledronate—osteoporosis	0.000111	0.000246	CcSEcCtD
Everolimus—Feeling abnormal—Estradiol—osteoporosis	0.00011	0.000246	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—IL6—osteoporosis	0.00011	0.000652	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CALCA—osteoporosis	0.00011	0.00065	CbGpPWpGaD
Everolimus—Rash—Zoledronate—osteoporosis	0.00011	0.000244	CcSEcCtD
Everolimus—Gastrointestinal pain—Estradiol—osteoporosis	0.00011	0.000244	CcSEcCtD
Everolimus—Dermatitis—Zoledronate—osteoporosis	0.00011	0.000244	CcSEcCtD
Everolimus—Headache—Zoledronate—osteoporosis	0.000109	0.000242	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—IL6—osteoporosis	0.000109	0.000641	CbGpPWpGaD
Everolimus—MTOR—Disease—FGA—osteoporosis	0.000108	0.000638	CbGpPWpGaD
Everolimus—Vomiting—Conjugated Estrogens—osteoporosis	0.000107	0.000237	CcSEcCtD
Everolimus—Body temperature increased—Estradiol—osteoporosis	0.000106	0.000236	CcSEcCtD
Everolimus—Abdominal pain—Estradiol—osteoporosis	0.000106	0.000236	CcSEcCtD
Everolimus—Rash—Conjugated Estrogens—osteoporosis	0.000106	0.000235	CcSEcCtD
Everolimus—Dermatitis—Conjugated Estrogens—osteoporosis	0.000106	0.000234	CcSEcCtD
Everolimus—Headache—Conjugated Estrogens—osteoporosis	0.000105	0.000233	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—IL6—osteoporosis	0.000104	0.000613	CbGpPWpGaD
Everolimus—Nausea—Zoledronate—osteoporosis	0.000103	0.00023	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR—IL6—osteoporosis	0.000103	0.00061	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MTHFR—osteoporosis	0.000103	0.000607	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—IL6—osteoporosis	0.000103	0.000607	CbGpPWpGaD
Everolimus—MTOR—Immune System—PSMA2—osteoporosis	0.000103	0.000607	CbGpPWpGaD
Everolimus—MTOR—Immune System—PSMA5—osteoporosis	0.000103	0.000607	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IRS2—osteoporosis	0.000102	0.000604	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—IL6—osteoporosis	0.000102	0.000604	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TLN1—osteoporosis	0.000101	0.000597	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	0.0001	0.00059	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KL—osteoporosis	9.99e-05	0.00059	CbGpPWpGaD
Everolimus—Nausea—Conjugated Estrogens—osteoporosis	9.95e-05	0.000221	CcSEcCtD
Everolimus—Hypersensitivity—Estradiol—osteoporosis	9.88e-05	0.000219	CcSEcCtD
Everolimus—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	9.86e-05	0.000582	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—IRS2—osteoporosis	9.82e-05	0.00058	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IRS2—osteoporosis	9.78e-05	0.000578	CbGpPWpGaD
Everolimus—MTOR—Disease—ENO1—osteoporosis	9.63e-05	0.000568	CbGpPWpGaD
Everolimus—Asthenia—Estradiol—osteoporosis	9.62e-05	0.000214	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR in disease—IL6—osteoporosis	9.62e-05	0.000568	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—IL6—osteoporosis	9.62e-05	0.000568	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—osteoporosis	9.62e-05	0.000568	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—IL6—osteoporosis	9.53e-05	0.000563	CbGpPWpGaD
Everolimus—Pruritus—Estradiol—osteoporosis	9.49e-05	0.000211	CcSEcCtD
Everolimus—MTOR—Disease—PSMA2—osteoporosis	9.49e-05	0.00056	CbGpPWpGaD
Everolimus—MTOR—Disease—PSMA5—osteoporosis	9.49e-05	0.00056	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—IL6—osteoporosis	9.45e-05	0.000558	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—IL6—osteoporosis	9.41e-05	0.000555	CbGpPWpGaD
Everolimus—Diarrhoea—Estradiol—osteoporosis	9.17e-05	0.000204	CcSEcCtD
Everolimus—MTOR—Innate Immune System—IRS1—osteoporosis	8.93e-05	0.000527	CbGpPWpGaD
Everolimus—Dizziness—Estradiol—osteoporosis	8.87e-05	0.000197	CcSEcCtD
Everolimus—MTOR—Disease—CALCA—osteoporosis	8.84e-05	0.000522	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—P4HB—osteoporosis	8.72e-05	0.000515	CbGpPWpGaD
Everolimus—MTOR—Immune System—KL—osteoporosis	8.69e-05	0.000513	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—IRS1—osteoporosis	8.58e-05	0.000506	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IRS1—osteoporosis	8.54e-05	0.000504	CbGpPWpGaD
Everolimus—Vomiting—Estradiol—osteoporosis	8.53e-05	0.000189	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—osteoporosis	8.52e-05	0.000503	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTH—osteoporosis	8.49e-05	0.000501	CbGpPWpGaD
Everolimus—Rash—Estradiol—osteoporosis	8.45e-05	0.000188	CcSEcCtD
Everolimus—Dermatitis—Estradiol—osteoporosis	8.45e-05	0.000188	CcSEcCtD
Everolimus—Headache—Estradiol—osteoporosis	8.4e-05	0.000187	CcSEcCtD
Everolimus—MTOR—Innate Immune System—IL6R—osteoporosis	8.39e-05	0.000495	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RAP1A—osteoporosis	8.34e-05	0.000492	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CNR2—osteoporosis	8.27e-05	0.000488	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NFATC1—osteoporosis	8.14e-05	0.00048	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—DKK1—osteoporosis	8.07e-05	0.000477	CbGpPWpGaD
Everolimus—MTOR—Disease—KL—osteoporosis	8.03e-05	0.000474	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6R—osteoporosis	8.02e-05	0.000474	CbGpPWpGaD
Everolimus—Nausea—Estradiol—osteoporosis	7.96e-05	0.000177	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—ADCY5—osteoporosis	7.83e-05	0.000462	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—WNT1—osteoporosis	7.77e-05	0.000459	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SPP1—osteoporosis	7.57e-05	0.000447	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGA—osteoporosis	7.56e-05	0.000447	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTHLH—osteoporosis	7.03e-05	0.000415	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—BMP2—osteoporosis	7.03e-05	0.000415	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—IL6—osteoporosis	6.99e-05	0.000412	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGB—osteoporosis	6.88e-05	0.000406	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IRS2—osteoporosis	6.85e-05	0.000404	CbGpPWpGaD
Everolimus—MTOR—Immune System—AGER—osteoporosis	6.83e-05	0.000403	CbGpPWpGaD
Everolimus—MTOR—Immune System—ADCY5—osteoporosis	6.81e-05	0.000402	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—LEP—osteoporosis	6.7e-05	0.000396	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PSMA2—osteoporosis	6.64e-05	0.000392	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PSMA5—osteoporosis	6.64e-05	0.000392	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—IL6—osteoporosis	6.55e-05	0.000387	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ESR1—osteoporosis	6.4e-05	0.000378	CbGpPWpGaD
Everolimus—MTOR—Disease—ADCY5—osteoporosis	6.29e-05	0.000371	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CALCA—osteoporosis	6.19e-05	0.000365	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—POMC—osteoporosis	6.01e-05	0.000355	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IRS1—osteoporosis	5.98e-05	0.000353	CbGpPWpGaD
Everolimus—MTOR—Immune System—IRS2—osteoporosis	5.96e-05	0.000352	CbGpPWpGaD
Everolimus—MTOR—Disease—MTHFR—osteoporosis	5.78e-05	0.000341	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—POMC—osteoporosis	5.76e-05	0.00034	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PKM—osteoporosis	5.67e-05	0.000335	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—FDPS—osteoporosis	5.67e-05	0.000335	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KL—osteoporosis	5.62e-05	0.000332	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6R—osteoporosis	5.62e-05	0.000332	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IGF1—osteoporosis	5.54e-05	0.000327	CbGpPWpGaD
Everolimus—MTOR—Disease—IRS2—osteoporosis	5.5e-05	0.000325	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PGLS—osteoporosis	5.37e-05	0.000317	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GPD2—osteoporosis	5.37e-05	0.000317	CbGpPWpGaD
Everolimus—MTOR—Immune System—IRS1—osteoporosis	5.2e-05	0.000307	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PNP—osteoporosis	4.91e-05	0.00029	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ATIC—osteoporosis	4.91e-05	0.00029	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6R—osteoporosis	4.89e-05	0.000289	CbGpPWpGaD
Everolimus—MTOR—Disease—IRS1—osteoporosis	4.8e-05	0.000284	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MYC—osteoporosis	4.75e-05	0.000281	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TGFB1—osteoporosis	4.74e-05	0.00028	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6R—osteoporosis	4.51e-05	0.000266	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ADCY5—osteoporosis	4.4e-05	0.00026	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SPP1—osteoporosis	4.26e-05	0.000252	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CA2—osteoporosis	4.18e-05	0.000247	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—OXCT1—osteoporosis	4.18e-05	0.000247	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MGLL—osteoporosis	4.07e-05	0.00024	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IRS2—osteoporosis	3.85e-05	0.000227	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—LEP—osteoporosis	3.77e-05	0.000223	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—osteoporosis	3.74e-05	0.000221	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL1B—osteoporosis	3.72e-05	0.000219	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ESR1—osteoporosis	3.6e-05	0.000213	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—osteoporosis	3.57e-05	0.000211	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—IDH2—osteoporosis	3.46e-05	0.000204	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IRS1—osteoporosis	3.36e-05	0.000199	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MYC—osteoporosis	3.33e-05	0.000197	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TGFB1—osteoporosis	3.32e-05	0.000196	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP27A1—osteoporosis	3.25e-05	0.000192	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—POMC—osteoporosis	3.24e-05	0.000191	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ACP5—osteoporosis	3.17e-05	0.000187	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6R—osteoporosis	3.16e-05	0.000187	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IGF1—osteoporosis	3.12e-05	0.000184	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TPI1—osteoporosis	2.94e-05	0.000174	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—P4HB—osteoporosis	2.77e-05	0.000163	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GAPDH—osteoporosis	2.72e-05	0.00016	CbGpPWpGaD
Everolimus—MTOR—Disease—MYC—osteoporosis	2.67e-05	0.000158	CbGpPWpGaD
Everolimus—MTOR—Disease—TGFB1—osteoporosis	2.67e-05	0.000157	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—RAP1A—osteoporosis	2.65e-05	0.000156	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—osteoporosis	2.5e-05	0.000148	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—osteoporosis	2.18e-05	0.000129	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ENO1—osteoporosis	2.14e-05	0.000126	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PSMA2—osteoporosis	2.11e-05	0.000124	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PSMA5—osteoporosis	2.11e-05	0.000124	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—osteoporosis	2.01e-05	0.000119	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MYC—osteoporosis	1.87e-05	0.000111	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TGFB1—osteoporosis	1.87e-05	0.00011	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP19A1—osteoporosis	1.71e-05	0.000101	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—osteoporosis	1.41e-05	8.31e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ADCY5—osteoporosis	1.4e-05	8.25e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GPX1—osteoporosis	1.39e-05	8.22e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MTHFR—osteoporosis	1.28e-05	7.58e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—POMC—osteoporosis	1.03e-05	6.07e-05	CbGpPWpGaD
